Clinical trials
Adenocarcinoma clinical trials
Below are recruiting adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 1,005 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06155383RecruitingPhase 2
Surgery and immunotherapy combo for stomach cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06234306Recruiting
Genetic testing for small bowel cancer
This trial studies the genetic makeup of small bowel adenocarcinoma to find better treatments. It involves testing leftover tumor tissue from past biopsies or surgeries.
Aarhus NAges 18 years+ - NCT06163729RecruitingPhase 2
Testing camrelizumab plus chemo and radiation before/after surgery for stomach-esophagus cancer
This trial tests combining the immunotherapy drug camrelizumab with chemotherapy and radiation before and after surgery for a specific type of stomach-esophagus cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–80 - NCT07872722RecruitingPhase 2
Study of two immunotherapies plus chemotherapy before surgery for stomach cancer
This trial tests a new approach for stomach cancer that hasn't spread. You'd get a combination of an investigational drug targeting a specific protein on cancer cells, an immunotherapy that helps your immune system fight cancer, and standard chemotherapy before surgery. The goal is to see if this makes the tumor shrink more and improves outcomes.
SaitamaAges 18 years+ - NCT06266832RecruitingPhase 2
Short-course radiation with immunotherapy and chemo for rectal cancer
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
Hangzhou, ZhejiangAges 18 years+ - NCT06278545RecruitingPhase 2
Chemotherapy for unremovable small bowel cancer
This trial tests two standard chemotherapy combinations (FOLFIRINOX and FOLFOX) in people with small bowel adenocarcinoma that cannot be removed by surgery or has spread. It aims to see which works better for people who haven't had chemotherapy before.
DijonAges 18 years+ - NCT06177041RecruitingPhase 3
M108 plus chemo for CLDN18.2-positive stomach cancer
This trial tests a new drug (M108) combined with standard chemotherapy (CAPOX) as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has a specific protein called Claudin 18.2. The goal is to see if adding M108 helps improve outcomes compared to chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06221748RecruitingPhase 2/Phase 3
Study of DV with cadonilimab for HER2-positive stomach cancer
This trial tests a combination of two drugs (DV and cadonilimab) for people with HER2-positive stomach or gastroesophageal junction cancer that has grown after first treatment. It aims to see if this combo can help when standard options have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT04694924Recruiting
Prostate cancer patient registry to track experiences
This study builds a database of people with localized or locally advanced prostate cancer to better understand patient-reported outcomes (your experiences and quality-of-life). It may help improve future care by collecting consistent feedback from patients.
Dendermonde, Oost-VlaanderenAges 18 years+ - NCT06415669RecruitingPhase 2
Combination therapy for advanced stomach cancer after immunotherapy
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
Fuzhou, FujianAges 18–75 - NCT07849608Recruiting
AI Tool to Assess Tumor Response After Pre-Surgery Treatment
This study is testing an AI tool (DeepTRG) that looks at tissue samples after pre-surgery treatment to see how well the tumor responded. It may help doctors better understand whether the treatment worked.
Shijiazhuang, None SelectedAges 18 years+ - NCT06341335RecruitingPhase 3
AK104 and AK109 plus paclitaxel for advanced stomach cancer
This trial tests a combination of two experimental immunotherapies (AK104 and AK109) with a standard chemo drug (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has grown after initial treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer better than chemo alone.
BeijingAges 18–75 - NCT07829081Recruiting
Watch-and-wait after immunotherapy for early-stage GI cancers
This study looks at whether some patients with early-stage stomach, colon, or rectal cancers that are mismatch repair-deficient (a genetic feature making them more likely to respond to immunotherapy) can safely avoid surgery and instead be monitored closely after treatment with immunotherapy. It aims to confirm if this watch-and-wait approach is as effective and helps patients avoid major operations.
BaselAges 18 years+ - NCT06196697RecruitingPhase 2
New immunotherapy combo for advanced stomach cancer
This clinical trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus chemotherapy as the first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if this combination helps control the cancer better than standard therapy.
HarbinAges 18–75 - NCT06482788RecruitingPhase 2
Immunotherapy plus chemo before & after junction cancer surgery
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07813884Recruiting
Study of a new treatment and blood test for colorectal cancer
This study looks at a new drug that may help treat colorectal cancer, and also tests a blood marker that could help diagnose it. It is for people who are already scheduled to have their colorectal tumor removed with surgery.
NiceAges 18 years+ - NCT07795528Recruiting
Blood test to monitor colon cancer after surgery
This trial uses a simple blood test to look for tiny bits of tumor DNA after colon cancer surgery. If found, it may help doctors catch any remaining cancer early and guide further treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05177133RecruitingPhase 2
First-line treatment for MSI-high stomach or esophagus cancer
This Phase 2 trial tests whether adding an anti–PD-1 immunotherapy (retifanlimab) and chemotherapy (capecitabine plus oxaliplatin, with leucovorin) works better for people with metastatic or inoperable stomach or gastroesophageal junction cancer that has defective mismatch repair (dMMR). If you’re eligible, it may help shrink tumors and slow the disease without needing prior chemotherapy for metastatic cancer.
AmsterdamAges 18 years+ - NCT06261359RecruitingPhase 2
CEND-1 plus chemo for first-line pancreatic cancer
This trial tests a new drug called CEND-1 combined with standard chemotherapy for people with advanced pancreatic cancer that has not been treated before. It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–80 - NCT05830812Recruiting
Improve accuracy of lung cancer invasiveness diagnosis during surgery
This trial looks to improve how doctors judge how “invasive” a small lung adenocarcinoma is while you’re having surgery. Better accuracy may help guide treatment decisions for people with early-stage, operable lung cancer.
Wuhan, HubeiAges 20–80 - NCT07751302Recruiting
Follow-up vs. chemo after surgery for early stomach cancer
This trial compares two approaches after surgery for early-stage stomach or GEJ cancer: close monitoring (follow-up) vs. adjuvant chemotherapy (chemo given after surgery). It aims to see if follow-up alone is as good as chemo for patients with this stage, potentially avoiding chemo side effects.
Xi'an, ShaanxiAges 18 years+ - NCT06587425RecruitingPhase 2
Combination therapy for CLDN18.2-positive advanced stomach cancer
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07744087Recruiting
Comparing two surgical methods for removing tumors near the pancreas
This trial compares two types of surgery to remove tumors that start near the pancreas but not in it. The goal is to see if a newer, less invasive method works as well as the standard approach, which may mean fewer cuts and a faster recovery.
Chongqing, Chongqing MunicipalityAges 18–75
Hear when a new Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adenocarcinoma?
- Yes. Clin2 currently lists 1,005 recruiting adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.